| 中文名 | VcMMAE |
|---|---|
| 英文名 | vc-mmae |
| 中文别名 |
VcMMAE,用于偶联抗体
马来酰亚胺己酰基-缬氨酸-瓜氨酸-对氨基苄氧羰基单甲基耳他汀 E 4-((S)-2-((S)-2-(6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺)-3-甲基丁酰胺)-5-脲基戊酰胺)苄基((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-羟基-1-苯丙烷-2-基)氨基)-1-甲氧基-2-甲基-3-氧代丙基)吡咯烷-1-基)-3-甲氧基-5-甲基-1-氧代庚-4-基)(甲基)氨基)-3-甲基-1-氧代丁烷-2-基)氨基)-3-甲基-1-氧代丁烷-2-基)(甲基)氨基甲酸酯 VCMMAE/VCMMAE/MC-VC-PAB-MMAE/含量 单甲基奥瑞他汀E 抗体偶联活性分子MC-Val-Cit-PAB-MMAE VCMMAE 单甲基奥瑞他汀E VCMMAE游离态 马来酰亚胺己酰基-缬氨酸-瓜氨酸-对氨基苄氧羰基单甲基奥瑞他汀 E VCMMAE,用于偶联抗体 |
| 英文别名 |
4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-Uriedidopenamiamido)benzyl((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S),2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y
Maleimidocaproyl-valine-citrulline-p-aminobenzyloxycbonyl monomethylauristatin E 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y N-[[[4-[[N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide 4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohtan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)cbamate Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E L-Valinamide, N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-met MC-VC-PAB-MMAE MC-VC-PABC-MMAE 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-((S)-2-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y Vedotin Brentuximab Impurity 1 (Vedotin) [4-[[(2S)-5-(cbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o EOS-60990 VcMMAE(Synonyms: mc-vc-PAB-MMAE) VeMMAE Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycbonyl-monomethyl auristatin E MC-Val-Cit-PAB-MMAE MC-VC-PAB-MMAE,MC-Val-Cit-PAB-MMAE maleimido-caproyl-val-Cit-PAB-MMAE VcMMAE (mc-vc-PAB-MMAE) VC-MMAE;VC MMAE N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(5S,8S,11S,12R)-11-[(2S)-2-butanyl]-12-(2-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenyl-2-propanyl]amino}-1-methoxy-2-methyl-3-oxop ;ropyl]-1-pyrrolidinyl}-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl}-N-carbamoyl-L-ornithinamide 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-((S)-2-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohtan-4-yl)(methyl)amino)-3-methylbutanamido)-3-methyl-1-oxobutan-2-yl)(methyl)cbamate MC-VAL-CIT-PABC-MMAE [4-[[(2S)-5-(cbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxohtan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcbamate |
| 描述 | VcMMAE是抗体药物复合体的一部分 (drug-linker conjugate for ADC),具有抗癌活性,它由MMAE和Vc连接而成。 |
|---|---|
| 相关类别 | |
| 体外研究 | 单甲基auristatin E(MMAE)在CD30 +癌细胞中从SGN-35有效释放,并且由于其膜通透性,能够对旁观者细胞发挥细胞毒活性[1]。 MMAE以与有丝分裂停滞相关的方案和剂量依赖性方式使结肠直肠癌和胰腺癌细胞对IR敏感。放射增敏作用可通过降低克隆形成存活率和增加辐射细胞中DNA双链断裂来证明[2]。 |
| 体内研究 | 单甲基auristatin E(MMAE)与IR结合导致肿瘤生长延迟,肿瘤靶向ACPP-cRGD-MMAE与IR在异种移植模型中产生更强大且显着延长的肿瘤消退[2]。 |
| 细胞实验 | 收获单甲基auristatin E(MMAE,5nM)和电离辐射(IR)处理的细胞,并在具有蛋白酶和磷酸酶抑制剂的RIPA缓冲液中裂解。使用4-12%Bis-Tris凝胶对30μg裂解物进行电泳,转移至PVDF膜并与指定的一抗孵育。印迹由ECL开发。 |
| 动物实验 | 将6-8周龄雌性无胸腺nu / nu小鼠皮下注射到1×1基质胶和PBS溶液中的5×106 HCT-116或PANC-1细胞的大腿中。用IR或静脉内(IV)注射ACPP-cRGD-MMAE(6nmol /天,总共18nmol,iv)处理小鼠,收获肿瘤组织,固定福尔马林并石蜡包埋,然后用指定的抗体染色。第一抗体以1:250稀释度使用,并使用DAB作为使用UltraMap系统的发色团显现。 |
| 参考文献 |
[3]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1. |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 1347.6±65.0 °C at 760 mmHg |
| 分子式 | C68H105N11O15 |
| 分子量 | 1316.626 |
| 闪点 | 768.8±34.3 °C |
| 精确质量 | 1315.779175 |
| LogP | 6.04 |
| 蒸汽压 | 0.0±0.3 mmHg at 25°C |
| 折射率 | 1.556 |
| 储存条件 | 2-8℃ |